Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

阿尔茨海默病中的 Kappa/Lambda 轻链分型

卷 19, 期 1, 2022

发表于: 31 January, 2022

页: [84 - 93] 页: 10

弟呕挨: 10.2174/1567205019666220131101334

价格: $65

conference banner
摘要

背景：阿尔茨海默病是一种以记忆丧失和认知障碍为特征的进行性神经退行性疾病。根据症状事件诊断阿尔茨海默病仍然是一项令人费解的任务。开发一种基于生物标志物、低成本和高通量的测试，易于应用于临床实验室，极大地影响了疾病的快速和可靠检测。目的：本研究旨在开发一种准确、灵敏、可靠的阿尔茨海默病诊断筛查工具，可显着降低现有方法的成本和时间。 方法：我们采用基于 MALDI-TOF-MS 的方法与使用亲和捕获树脂的微亲和色谱富集方法相结合，以确定对照组和 AD 患者的血清 kappa (κ) 和 lambda (λ) 轻链水平。 结果：我们观察到 AD 患者和对照组之间的 kappa 轻链与 lambda 轻链 (κLC/λLC) 比率存在统计学显着差异（平均差异 -0,409；% 95 CI：- 0.547 至 -0.269；p<0.001）。我们的方法证明了区分 AD 和对照的更高灵敏度 (100.00%) 和特异性 (71.43%)。 结论：我们开发了一种高通量筛选试验，采用新的样品富集方法来确定与 AD 诊断相关的 κLC/λLC 比率。经过进一步验证，我们相信我们的测试具有临床实验室的潜力。

关键词: 阿尔茨海默病，MALDI-TOF-MS，筛选工具，微亲和层析，亲和捕获树脂，κ轻链，比率，λ轻链比率

« Previous
[1]
Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer’s Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement 2017; 13(5): 561-71.
[2]
Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 2018; 141(7): 1917-33.
[http://dx.doi.org/10.1093/brain/awy132] [PMID: 29850777]
[3]
2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020; 16(3): 391-460.
[http://dx.doi.org/10.1002/alz.12068]
[4]
Patterson C. World Alzheimer Report 2018 - The state of the art of dementia research: New frontiers. UK. Alzheimer’s Dis Int London 2018; 1-48.
[5]
Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 2018; 8(1): 17368.
[http://dx.doi.org/10.1038/s41598-018-35766-w] [PMID: 30478269]
[6]
Zhou W, Zhang J, Ye F, et al. Plasma neurofilament light chain levels in Alzheimer’s disease. Neurosci Lett 2017; 650: 60-4.
[http://dx.doi.org/10.1016/j.neulet.2017.04.027] [PMID: 28428015]
[7]
Jin M, Cao L, Dai YP. Role of neurofilament light chain as a potential biomarker for Alzheimer’s disease: A correlative meta-analysis. Front Aging Neurosci 2019; 11: 254.
[http://dx.doi.org/10.3389/fnagi.2019.00254] [PMID: 31572170]
[8]
Massa F, Meli R, Morbelli S, Nobili F, Pardini M. Serum neurofilament light chain rate of change in Alzheimer’s disease: Potentials applications and notes of caution. Ann Transl Med 2019; 7(S3)(Suppl. 3): S133-3.
[http://dx.doi.org/10.21037/atm.2019.05.81] [PMID: 31576340]
[9]
O’Bryant SE, Mielke MM, Rissman RA, et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement 2017; 13(1): 45-58.
[http://dx.doi.org/10.1016/j.jalz.2016.09.014] [PMID: 27870940]
[10]
Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther 2018; 10(1): 71.
[http://dx.doi.org/10.1186/s13195-018-0404-9] [PMID: 30055655]
[11]
Groot Kormelink T, Powe DG, Kuijpers SA, et al. Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. Oncotarget 2014; 5(10): 3159-67.
[http://dx.doi.org/10.18632/oncotarget.1868] [PMID: 24931643]
[12]
Qiu Y, Korteweg C, Chen Z, et al. Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. Mod Pathol 2012; 25(1): 36-45.
[http://dx.doi.org/10.1038/modpathol.2011.139] [PMID: 21909078]
[13]
Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 2007; 18(4): 1239-45.
[http://dx.doi.org/10.1681/ASN.2006111299] [PMID: 17360948]
[14]
Migrino RQ, Hari P, Gutterman DD, et al. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol 2010; 145(1): 67-8.
[http://dx.doi.org/10.1016/j.ijcard.2009.04.044] [PMID: 19446898]
[15]
Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer’s disease. (review) Biomed Rep 2016; 4(5): 519-22.
[16]
Hegen H, Walde J, Milosavljevic D, et al. Free light chains in the cerebrospinal fluid. Comparison of different methods to determine intrathecal synthesis. Clin Chem Lab Med 2019; 57(10): 1574-86.
[http://dx.doi.org/10.1515/cclm-2018-1300] [PMID: 31112501]
[17]
Altinier S, Puthenparampil M, Zaninotto M, et al. Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands. Clin Chim Acta 2019; 496: 117-20.
[http://dx.doi.org/10.1016/j.cca.2019.06.016] [PMID: 31233736]
[18]
Jenkins MA, Cheng L, Ratnaike S. Multiple sclerosis: Use of light-chain typing to assist diagnosis. Ann Clin Biochem 2001; 38(Pt 3): 235-41.
[http://dx.doi.org/10.1258/0004563011900669] [PMID: 11392498]
[19]
Bayart JL, Muls N, van Pesch V. Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute? Acta Neurol Scand 2018; 138(4): 352-8.
[http://dx.doi.org/10.1111/ane.12969] [PMID: 29900542]
[20]
Siegel D, Bilotti E, van Hoeven KH. Serum free light chain analysis for diagnosis, monitoring, and prognosis of monoclonal gammopathies. Lab Med 2009; 40(6): 363-6.
[http://dx.doi.org/10.1309/LMPHODC7R1L0MEWW]
[21]
Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol 2010; 85(10): 787-90.
[http://dx.doi.org/10.1002/ajh.21815] [PMID: 20721885]
[22]
Kumar S, Larson DR, Dispenzieri A, et al. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. Blood Cancer J 2019; 9(6): 49.
[http://dx.doi.org/10.1038/s41408-019-0210-z] [PMID: 31101803]
[23]
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 263-9.
[http://dx.doi.org/10.1016/j.jalz.2011.03.005] [PMID: 21514250]
[24]
Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 2016; 62(10): 1334-44.
[http://dx.doi.org/10.1373/clinchem.2015.253740] [PMID: 27540026]
[25]
Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3(1): 32-5.
[http://dx.doi.org/10.1002/1097-0142(1950)3:1<32:AID-CNCR2820030106>3.0.CO;2-3] [PMID: 15405679]
[26]
Sepiashvili L, Kohlhagen MC, Snyder MR, et al. Direct detection of monoclonal free light chains in serum by use of immunoenrichment-coupled MALDI-TOF mass spectrometry. Clin Chem 2019; 65(8): 1015-22.
[http://dx.doi.org/10.1373/clinchem.2018.299461] [PMID: 31171529]
[27]
Leung N. Chapter 8: Clinical Tests for Monoclonal Proteins. American Soc Nephrol 2016. Available from: .https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter8.pdf
[28]
Bradwell A, Harding S, Fourrier N, et al. Prognostic utility of intact immunoglobulin Ig’κ/Ig’λ ratios in multiple myeloma patients. Leukemia 2013; 27(1): 202-7.
[http://dx.doi.org/10.1038/leu.2012.159] [PMID: 22699454]
[29]
Ludwig H, Milosavljevic D, Zojer N, et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013; 27(1): 213-9.
[http://dx.doi.org/10.1038/leu.2012.197] [PMID: 22955329]
[30]
Paolini L, Di Noto G, Maffina F, et al. Comparison of Hevylite™ IgA and IgG assay with conventional techniques for the diagnosis and follow-up of plasma cell dyscrasia. Ann Clin Biochem 2015; 52(Pt 3): 337-45.
[http://dx.doi.org/10.1177/0004563214564225] [PMID: 25468997]
[31]
Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55(8): 1517-22.
[http://dx.doi.org/10.1373/clinchem.2009.126664] [PMID: 19520758]
[32]
Nakano T, Miyazaki S, Takahashi H, et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006; 44(5): 522-32.
[http://dx.doi.org/10.1515/CCLM.2006.118] [PMID: 16681419]
[33]
Felhofer JL, Blanes L, Garcia CD. Recent developments in instrumentation for capillary electrophoresis and microchip-capillary electrophoresis. Electrophoresis 2010; 31(15): 2469-86.
[http://dx.doi.org/10.1002/elps.201000203]
[34]
Bossuyt X, Mariën G. False-negative results in detection of monoclonal proteins by capillary zone electrophoresis: a prospective study. Clin Chem 2001; 47(8): 1477-9.
[http://dx.doi.org/10.1093/clinchem/47.8.1477] [PMID: 11468244]
[35]
McCudden CR, Jacobs JFM, Keren D, Caillon H, Dejoie T, Andersen K. Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. Clin Biochem 2018; 51: 72-9.
[http://dx.doi.org/10.1016/j.clinbiochem.2017.08.013]
[36]
Kim HS, Kim HS, Shin KS, et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. BioMed Res Int 2014; 2014647238
[http://dx.doi.org/10.1155/2014/647238] [PMID: 24971342]
[37]
Ladwig PM, Barnidge DR, Willrich MAV. Quantification of the IgG2/4 kappa monoclonal therapeutic eculizumab from serum using isotype specific affinity purification and microflow LC-ESI-Q-TOF mass spectrometry. Journal of the American Society for Mass Spectrometry Springer New York LLC 2017; LLC: 811-7.
[http://dx.doi.org/10.1007/s13361-016-1566-y]
[38]
Hermans P, Adams H, Detmers F. Purification of antibodies and antibody fragments using CaptureSelect™ affinity resins. Methods Mol Biol 2014; 1131: 297-314.
[http://dx.doi.org/10.1007/978-1-62703-992-5_19] [PMID: 24515474]
[39]
Kaplan B, Livneh A, Sela B-A. Immunoglobulin free light chain dimers in human diseases. Scientific World J 2011; 11: 726-35.
[40]
Mossuto MF. Disulfide bonding in neurodegenerative misfolding diseases. Int J Cell Biol 2013; 2013318319
[41]
Bechtel TJ, Weerapana E. From structure to redox: The diverse functional roles of disulfides and implications in disease. Proteomics 2017; 17(6): 10.
[42]
Perri ER, Thomas CJ, Parakh S, Spencer DM, Atkin JD. The unfolded protein response and the role of protein disulfide isomerase in neurodegeneration 2016. Available from:.www.frontiersin.org
[43]
Bienert GP, Schjoerring JK, Jahn TP. Membrane transport of hydrogen peroxide. Biochim Biophys Acta 2006. [Epub ahead of Print
[http://dx.doi.org/10.1016/j.bbamem.2006.02.015]
[44]
Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94(8): 1008-10.
[http://dx.doi.org/10.1161/01.RES.0000126569.75419.74] [PMID: 15044325]
[45]
Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutschmann OT. Alzheimer disease: Operating characteristics of PET - A meta-analysis. Radiol 2004; 231(1): 73-80.
[46]
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5(3): 228-34.
[http://dx.doi.org/10.1016/S1474-4422(06)70355-6] [PMID: 16488378]
[47]
Sjögren M, Vanderstichele H, Ågren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47(10): 1776-81.
[http://dx.doi.org/10.1093/clinchem/47.10.1776] [PMID: 11568086]
[48]
Guo Z, Zhang Q, Zou H, Guo B, Ni J. A method for the analysis of low-mass molecules by MALDI-TOF mass spectrometry. Anal Chem 2002; 74(7): 1637-41.
[http://dx.doi.org/10.1021/ac010979m] [PMID: 12033256]
[49]
Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: An emerging technology for microbial identification and diagnosis. Front Microbiol 2015; 6(AUG): 791.
[http://dx.doi.org/10.3389/fmicb.2015.00791] [PMID: 26300860]
[50]
Swiatly A, Horala A, Hajduk J, Matysiak J, Nowak-Markwitz E, Kokot ZJ. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer. BMC Cancer 2017; 17(1): 472.
[http://dx.doi.org/10.1186/s12885-017-3467-2] [PMID: 28683725]

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy